CN103768542A - Medicine for treating ascites due to liver cancer and preparation method thereof - Google Patents
Medicine for treating ascites due to liver cancer and preparation method thereof Download PDFInfo
- Publication number
- CN103768542A CN103768542A CN201410068364.3A CN201410068364A CN103768542A CN 103768542 A CN103768542 A CN 103768542A CN 201410068364 A CN201410068364 A CN 201410068364A CN 103768542 A CN103768542 A CN 103768542A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- herba
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicine for treating ascites due to liver cancer. The medicine comprises the following components in parts by weight: 15-19 parts of radix bupleuri, 15-19 parts of bighead atractylodes rhizome, 20-24 parts of white peony root, 15-19 parts of dried tangerine peel, 10-14 parts of chrysanthemum morifolium, 10-14 parts of Chinese angelica, 15-19 parts of salviae miltiorrhizae, 20-24 pats of fiveleaf akebia fruit, 5-9 parts of safflower, 15-19 parts of poria, 20-24 parts of sculellaria barbata, 20-24 parts of rhizoma sparganic, 30-34 parts of polygonum cuspidatum, 10-14 parts of moutan bark, 20-24 parts of dandelion, 20-24 parts of solanum nigrum, 20-24 parts of oriental wormwood, 20-24 parts of curcuma zedoary, 20-24 parts of aspongopus, 20-24 parts of indian iphigenia bulb, 10-14 parts of spina gleditsiae, 20-24 parts of manyleaf paris rhizome, 10-14 parts of fructus aurantii, 15-19 parts of artemisia anomala, 20-24 parts of raw oyster, 20-24 parts of turtle shell, 10-14 parts of costustoot, 15-19 parts of codonopsis pilosula, 30-34 parts of selfheal, 15-19 parts of salvia chinensis, 15-19 parts of verbena, 5-9 parts of rhizoma alismatis, 5-9 parts of polyporus umbellatus, 10-14 parts of plantain seed, 10-14 parts of frankincense, 10-14 parts of myrrh, 10-14 parts of corydalis tuber, 10-14 parts of radix curcumae, 10-14 parts of toad skin, 5-9 parts of greater celandine herb, 5-9 parts of szechwan Chinaberry fruit, 10-14 parts of sappanwood, 3-7 parts of radix phytolaccae, 10-14 parts of paniculate swallowwort root, and 3-7 parts of semen pharbitidis. The effective rate of the medicine in treating ascites due to liver cancer can be 73 percent.
Description
Technical field
The present invention relates to a kind of medicine of Hepatoma therapy, specifically, relate to medicine of a kind of Hepatoma therapy ascites and preparation method thereof, belong to Chinese medicine technical field.
Background technology
Hepatocarcinoma is one of China's common cancer, clinical manifestation mainly contain hepatalgia, poor appetite, weak, become thin, heating, jaundice and ascites, in recent years due to hepatitis, fatty liver, alcoholic liver patient increase and diet, contaminated drinking water increase the weight of cause the sickness rate of hepatocarcinoma obviously to rise.
Hepatic ascites is one of modal complication of advanced liver cancer, belong to the one of malignant ascite, liver cancer patient occurs that ascites is mainly that albumin is synthetic to be reduced because chronic liver function damage makes, it is unbalance that plasma colloid osmotic pressure decline or portal hypertension cause the inside and outside water metabolism of cell, and intracellular water runs off and forms ascites to extracellular.The symptoms such as hepatic ascites patient Chang Hui shows as dry mouth and throat, thirsty.The appearance of hepatic ascites symptom is having a strong impact on the quality of life of vast liver cancer patient, has also increased the difficulty of mid and late liver cancer treatment simultaneously, and severe patient can threaten patient's life.
Realizing in process of the present invention, inventor finds that prior art at least has the following disadvantages: aspect treatment hepatic ascites, doctor trained in Western medicine there is no good therapy, adopts that ascites dialysis, puncture discharge water, abdominal cavity injection, defeated albumin and diuretic more.Though can temporarily remove patient suffering, cure the symptoms, not the disease, easily repeatedly.First, application diuretic, frequent drawing liquid, intracavitary administration medicine etc., often bring very large misery to patient, and toxic and side effects is huge, and curative effect is very micro-.Secondly, repeatedly carry out losing a large amount of body fluid albumen in drawing liquid process, make body weaker, cause other organ dysfunctions thereby easily merge various infection.
At present, also occurred clinically the Chinese medicine of multiple treatment hepatic ascites, though obtained certain curative effect, effect is not ideal.
Summary of the invention
The technical problem to be solved in the present invention is for above deficiency, medicine of a kind of Hepatoma therapy ascites and preparation method thereof is provided, overcome existing drug side effect larger, relapse rate is high, the less-than-ideal defect of effect, adopt Drug therapy hepatic ascites of the present invention, therapeutic effect is obvious, and relapse rate is low.
For solving the problems of the technologies described above, the technical solution adopted in the present invention is: a kind of medicine of Hepatoma therapy ascites, is characterized in that: the active ingredient of described medicine comprises by weight: Radix Bupleuri 15-19 part, Rhizoma Atractylodis Macrocephalae 15-19 part, Radix Paeoniae Alba 20-24 part, Pericarpium Citri Reticulatae 15-19 part, Flos Chrysanthemi 10-14 part, Radix Angelicae Sinensis 10-14 part, Radix Salviae Miltiorrhizae 15-19 part, Fructus Akebiae 20-24 part, Flos Carthami 5-9 part, Poria 15-19 part, Herba Scutellariae Barbatae 20-24 part, Rhizoma Sparganii 20-24 part, Rhizoma Polygoni Cuspidati 30-34 part, Cortex Moutan 10-14 part, Herba Taraxaci 20-24 part, Herba Solani Nigri 20-24 part, Herba Artemisiae Scopariae 20-24 part, Rhizoma Curcumae 20-24 part, Aspongopus 20-24 part, Pseudobulbus Cremastrae Seu Pleiones 20-24 part, Spina Gleditsiae 10-14 part, Rhizoma Paridis 20-24 part, Fructus Aurantii 10-14 part, Herba Artemisiae Anomalae 15-19 part, Concha Ostreae 20-24 part, Carapax Trionycis 20-24 part, Radix Aucklandiae 10-14 part, Radix Codonopsis 15-19 part, Spica Prunellae 30-34 part, Herba Salviae Chinensis 15-19 part, Herba Verbenae 15-19 part, Rhizoma Alismatis 5-9 part, Polyporus 5-9 part, Semen Plantaginis 10-14 part, Olibanum 10-14 part, Myrrha 10-14 part, Rhizoma Corydalis 10-14 part, Radix Curcumae 10-14 part, Cutis Bufonis 10-14 part, Herba Chelidonii 5-9 part, Fructus Toosendan 5-9 part, Lignum Sappan 10-14 part, Radix Phytolaccae 3-7 part, Radix Cynanchi Paniculati 10-14 part and Semen Pharbitidis 3-7 part.
A kind of prioritization scheme, the active ingredient of described medicine comprises by weight: Radix Bupleuri 16-18 part, Rhizoma Atractylodis Macrocephalae 16-18 part, Radix Paeoniae Alba 21-23 part, Pericarpium Citri Reticulatae 16-18 part, Flos Chrysanthemi 11-13 part, Radix Angelicae Sinensis 11-13 part, Radix Salviae Miltiorrhizae 16-18 part, Fructus Akebiae 21-23 part, Flos Carthami 6-8 part, Poria 16-18 part, Herba Scutellariae Barbatae 21-23 part, Rhizoma Sparganii 21-23 part, Rhizoma Polygoni Cuspidati 31-33 part, Cortex Moutan 11-13 part, Herba Taraxaci 21-23 part, Herba Solani Nigri 21-23 part, Herba Artemisiae Scopariae 21-23 part, Rhizoma Curcumae 21-23 part, Aspongopus 21-23 part, Pseudobulbus Cremastrae Seu Pleiones 21-23 part, Spina Gleditsiae 11-13 part, Rhizoma Paridis 21-23 part, Fructus Aurantii 11-13 part, Herba Artemisiae Anomalae 16-18 part, Concha Ostreae 21-23 part, Carapax Trionycis 21-23 part, Radix Aucklandiae 11-13 part, Radix Codonopsis 16-18 part, Spica Prunellae 31-33 part, Herba Salviae Chinensis 16-18 part, Herba Verbenae 16-18 part, Rhizoma Alismatis 6-8 part, Polyporus 6-8 part, Semen Plantaginis 11-13 part, Olibanum 11-13 part, Myrrha 11-13 part, Rhizoma Corydalis 11-13 part, Radix Curcumae 11-13 part, Cutis Bufonis 11-13 part, Herba Chelidonii 6-8 part, Fructus Toosendan 6-8 part, Lignum Sappan 11-13 part, Radix Phytolaccae 4-6 part, Radix Cynanchi Paniculati 11-13 part and Semen Pharbitidis 4-6 part.
Further, the active ingredient of described medicine comprises by weight: 17 parts of Radix Bupleuri, 17 parts of the Rhizoma Atractylodis Macrocephalaes, 22 parts of the Radix Paeoniae Albas, 17 parts of Pericarpium Citri Reticulataes, 12 parts of Flos Chrysanthemi, 12 parts of Radix Angelicae Sinensis, 17 parts of Radix Salviae Miltiorrhizaes, 22 parts of Fructus Akebiaes, 7 parts, Flos Carthami, 17 parts, Poria, 22 parts of Herba Scutellariae Barbataes, 22 parts of Rhizoma Sparganii, 32 parts of Rhizoma Polygoni Cuspidati, 12 parts of Cortex Moutans, 22 parts of Herba Taraxacis, 22 parts of Herba Solani Nigris, 22 parts of Herba Artemisiae Scopariaes, 22 parts of Rhizoma Curcumae, 22 parts of Aspongopuss, 22 parts of Pseudobulbus Cremastrae Seu Pleioness, 12 parts of Spina Gleditsiaes, 22 parts of Rhizoma Paridis, 12 parts of Fructus Aurantiis, 17 parts of Herba Artemisiae Anomalaes, 22 parts of Concha Ostreae, 22 parts of Carapax Trionycis, 12 parts of the Radix Aucklandiae, 17 parts of Radix Codonopsis, 32 parts of Spica Prunellaes, 17 parts of Herba Salviae Chinensiss, 17 parts of Herba Verbenae, 7 parts of Rhizoma Alismatis, 7 parts of Polyporus, 12 parts of Semen Plantaginiss, 12 parts of Olibanums, 12 parts of Myrrhas, 12 parts of Rhizoma Corydalis, 12 parts of Radix Curcumaes, 12 parts of Cutis Bufonis, 7 parts of Herba Chelidoniis, 7 parts of Fructus Toosendans, 12 parts of Lignum Sappans, 5 parts of Radix Phytolaccaes, 5 parts of 12 parts of Radix Cynanchi Paniculatis and Semen Pharbitidiss.
Based on above Hepatoma therapy ascites medicine, the preparation method of this hepatic ascites medicine comprises the following steps:
A, take respectively each raw material according to weight portion;
B, Carapax Trionycis is faint yellow to surface with stir-baking in sand, takes out, quench in vinegar, and dry smashing to pieces, for subsequent use;
C, Radix Aucklandiae (roasted): get undried Radix Aucklandiae sheet, in iron wire plaque, use one deck toilet paper, one deck Radix Aucklandiae sheet, several layers of interval tilings, put in the other or drying chamber of stove fire, dry to simmer to contained volatile oil in the Radix Aucklandiae to ooze to paper, take out, for subsequent use;
D, Olibanum (processed): get the Olibanum of choosing clean, put in pot and fry and slightly see melting point to surface with slow fire, be slightly yellow, taking-up cools; Or fry while dissolving to surface, spray rice vinegar, continue stir-fry saturating to outer bright light, taking-up cools, for subsequent use;
E, Myrrha (processed): get the Myrrha of choosing clean put pot in slow fire fry slightly see melting point to surface, taking-up cools.Or fry slightly see fusing during to surface, spray rice vinegar, continue stir-fry saturating to outer bright light, taking-up cools, for subsequent use;
F, wine Rhizoma Corydalis: get clean Rhizoma Corydalis sheet or fragment, add yellow wine and mix thoroughly, vexed, put in pot and heat with slow fire, fried dry, taking-up cools, for subsequent use;
G, Rhizoma Atractylodis Macrocephalae (parched): processed with honey wheat bran is sprinkled in heat pot, adds Rhizoma Atractylodis Macrocephalae sheet in the time smoldering, fry to coke yellow, effusion burnt odor gas, take out, sieve removes processed with honey wheat bran, for subsequent use;
H, Radix Paeoniae Alba: get clean Radix Paeoniae Alba sheet, even with yellow wine sprinkling, slightly after profit, put an extremely micro-yellow of stir-fry in pot, for subsequent use;
J, remaining raw material and Carapax Trionycis (processed with vinegar) and Radix Aucklandiae (roasted), Olibanum (processed), Myrrha (processed), wine Rhizoma Corydalis, Rhizoma Atractylodis Macrocephalae (parched), Radix Paeoniae Alba are mixed, pulverize with pulverizer, crossing 120 mesh sieves becomes smalls, obtains the medicine of Hepatoma therapy ascites.
In step b, the weight ratio of described Carapax Trionycis and vinegar is 5:1.
In steps d, the weight ratio of described Olibanum and rice vinegar is 50:3.
In step e, the weight ratio of described Myrrha and rice vinegar is 50:3.
In step f, the weight ratio of described Rhizoma Corydalis and yellow wine is 5:1.
In step g, the weight ratio of the described Rhizoma Atractylodis Macrocephalae and processed with honey wheat bran is 10:1.
In step h, the weight ratio of the described Radix Paeoniae Alba and yellow wine is 10:1.
The pharmacology of above Chinese medicine is:
?radix Bupleuri, the Rhizoma Atractylodis Macrocephalae, the Radix Paeoniae Alba, Pericarpium Citri Reticulatae, Radix Codonopsis, Fructus Aurantii, Radix Aucklandiae (roasted), Herba Artemisiae Scopariae, Radix Curcumae, Aspongopus, Fructus Toosendan, Poria have effect of replenishing QI to invigorate the spleen, depressed liver-energy dispersing and QI regulating; Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Carthami, Cortex Moutan, Olibanum, Myrrha, Rhizoma Corydalis, Lignum Sappan, Radix Cynanchi Paniculati, Rhizoma Polygoni Cuspidati, Rhizoma Paridis, Rhizoma Curcumae, Rhizoma Sparganii, Herba Artemisiae Anomalae have effect of nourshing blood and promoting blood circulation, removing obstruction for relieving pain; Pseudobulbus Cremastrae Seu Pleiones, Flos Chrysanthemi, Fructus Akebiae, Herba Taraxaci, Herba Solani Nigri, Spina Gleditsiae, Spica Prunellae, Herba Verbenae, Herba Scutellariae Barbatae, Cutis Bufonis, Concha Ostreae, Carapax Trionycis, Herba Salviae Chinensis have heat-clearing and toxic substances removing, the effect of Xiao Disorder of invigorating blood circulation; Radix Phytolaccae, Semen Pharbitidis, Rhizoma Alismatis, Polyporus, Semen Plantaginis, Herba Chelidonii have effect of expelling fluid-retention, dispersing swelling and dissipating binds.Make eventually it jointly reach that resolving and invigoration therapies being applied simultaneously, diuretic disappear knot and the effect of not hindering healthy energy.
The present invention adopts above technical scheme, compared with prior art, have the following advantages: hepatic ascites patient is had to the eliminating stagnation effect of significantly relieving oedema or abdominal distension through diuresis or purgation, simultaneously can QI invigorating soothing liver and strengthening spleen, nourshing blood and promoting blood circulation pain relieving, hard masses softening and resolving Xiao Disorder, improve patient's life quality, through test, effective percentage can reach 80%.
Below in conjunction with the specific embodiment to technical scheme further instruction of the present invention.
The specific embodiment
Embodiment 1, a kind of medicine of Hepatoma therapy ascites, active ingredient comprises by weight: 15 parts of Radix Bupleuri, 19 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts of Radix Paeoniae Alba, 15 parts of Pericarpium Citri Reticulataes, 10 parts of Flos Chrysanthemi, 14 parts of Radix Angelicae Sinensis, 15 parts of Radix Salviae Miltiorrhizaes, 24 parts of Fructus Akebiaes, 5 parts, Flos Carthami, 15 parts, Poria, 20 parts of Herba Scutellariae Barbataes, 24 parts of Rhizoma Sparganii, 30 parts of Rhizoma Polygoni Cuspidati, 10 parts of Cortex Moutans, 20 parts of Herba Taraxacis, 20 parts of Herba Solani Nigris, 20 parts of Herba Artemisiae Scopariaes, 24 parts of Rhizoma Curcumae, 20 parts of Aspongopuss, 20 parts of Pseudobulbus Cremastrae Seu Pleioness, 10 parts of Spina Gleditsiaes, 20 parts of Rhizoma Paridis, 10 parts of Fructus Aurantiis, 15 parts of Herba Artemisiae Anomalaes, 20 parts of Concha Ostreae, 20 parts of Carapax Trionycis, 14 parts of the Radix Aucklandiae, 15 parts of Radix Codonopsis, 30 parts of Spica Prunellaes, 19 parts of Herba Salviae Chinensiss, 15 parts of Herba Verbenae, 5 parts of Rhizoma Alismatis, 5 parts of Polyporus, 10 parts of Semen Plantaginiss, 10 parts of Olibanums, 10 parts of Myrrhas, 10 parts of Rhizoma Corydalis, 10 parts of Radix Curcumaes, 10 parts of Cutis Bufonis, 5 parts of Herba Chelidoniis, 5 parts of Fructus Toosendans, 10 parts of Lignum Sappans, 10 parts of Radix Cynanchi Paniculatis, 4 parts of Radix Phytolaccaes, 3 parts of Semen Pharbitidiss.
Embodiment 2, a kind of medicine of Hepatoma therapy ascites, active ingredient comprises by weight: 19 parts of Radix Bupleuri, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 24 parts of the Radix Paeoniae Albas, 15 parts of Pericarpium Citri Reticulataes, 14 parts of Flos Chrysanthemi, 10 parts of Radix Angelicae Sinensis, 19 parts of Radix Salviae Miltiorrhizaes, 20 parts of Fructus Akebiaes, 9 parts, Flos Carthami, 19 parts, Poria, 24 parts of Herba Scutellariae Barbataes, 20 parts of Rhizoma Sparganii, 34 parts of Rhizoma Polygoni Cuspidati, 14 parts of Cortex Moutans, 24 parts of Herba Taraxacis, 24 parts of Herba Solani Nigris, 24 parts of Herba Artemisiae Scopariaes, 20 parts of Rhizoma Curcumae, 24 parts of Aspongopuss, 24 parts of Pseudobulbus Cremastrae Seu Pleioness, 14 parts of Spina Gleditsiaes, 24 parts of Rhizoma Paridis, 14 parts of Fructus Aurantiis, 19 parts of Herba Artemisiae Anomalaes, 24 parts of Concha Ostreae, 24 parts of Carapax Trionycis, 10 parts of the Radix Aucklandiae, 19 parts of Radix Codonopsis, 34 parts of Spica Prunellaes, 15 parts of Herba Salviae Chinensiss, 19 parts of Herba Verbenae, 9 parts of Rhizoma Alismatis, 9 parts of Polyporus, 14 parts of Semen Plantaginiss, 14 parts of Olibanums, 14 parts of Myrrhas, 14 parts of Rhizoma Corydalis, 14 parts of Radix Curcumaes, 14 parts of Cutis Bufonis, 9 parts of Herba Chelidoniis, 9 parts of Fructus Toosendans, 14 parts of Lignum Sappans, 6 parts of Radix Phytolaccaes, 7 parts of 14 parts of Radix Cynanchi Paniculatis and Semen Pharbitidiss.
Embodiment 3, a kind of medicine of Hepatoma therapy ascites, active ingredient comprises by weight: 17 parts of Radix Bupleuri, 17 parts of the Rhizoma Atractylodis Macrocephalaes, 22 parts of the Radix Paeoniae Albas, 17 parts of Pericarpium Citri Reticulataes, 12 parts of Flos Chrysanthemi, 12 parts of Radix Angelicae Sinensis, 17 parts of Radix Salviae Miltiorrhizaes, 22 parts of Fructus Akebiaes, 7 parts, Flos Carthami, 17 parts, Poria, 22 parts of Herba Scutellariae Barbataes, 22 parts of Rhizoma Sparganii, 32 parts of Rhizoma Polygoni Cuspidati, 12 parts of Cortex Moutans, 22 parts of Herba Taraxacis, 22 parts of Herba Solani Nigris, 22 parts of Herba Artemisiae Scopariaes, 22 parts of Rhizoma Curcumae, 22 parts of Aspongopuss, 22 parts of Pseudobulbus Cremastrae Seu Pleioness, 12 parts of Spina Gleditsiaes, 22 parts of Rhizoma Paridis, 12 parts of Fructus Aurantiis, 17 parts of Herba Artemisiae Anomalaes, 22 parts of Concha Ostreae, 22 parts of Carapax Trionycis, 12 parts of the Radix Aucklandiae, 17 parts of Radix Codonopsis, 32 parts of Spica Prunellaes, 17 parts of Herba Salviae Chinensiss, 17 parts of Herba Verbenae, 7 parts of Rhizoma Alismatis, 7 parts of Polyporus, 12 parts of Semen Plantaginiss, 12 parts of Olibanums, 12 parts of Myrrhas, 12 parts of Rhizoma Corydalis, 12 parts of Radix Curcumaes, 12 parts of Cutis Bufonis, 7 parts of Herba Chelidoniis, 7 parts of Fructus Toosendans, 12 parts of Lignum Sappans, 12 parts of Radix Cynanchi Paniculatis, 5 parts of 5 parts of Radix Phytolaccaes and Semen Pharbitidiss.
Embodiment 4, a kind of medicine of Hepatoma therapy ascites, active ingredient comprises by weight: 18 parts of Radix Bupleuri, 18 parts of the Rhizoma Atractylodis Macrocephalaes, 22 parts of the Radix Paeoniae Albas, 18 parts of Pericarpium Citri Reticulataes, 13 parts of Flos Chrysanthemi, 13 parts of Radix Angelicae Sinensis, 18 parts of Radix Salviae Miltiorrhizaes, 23 parts of Fructus Akebiaes, 8 parts, Flos Carthami, 18 parts, Poria, 23 parts of Herba Scutellariae Barbataes, 23 parts of Rhizoma Sparganii, 33 parts of Rhizoma Polygoni Cuspidati, 13 parts of Cortex Moutans, 23 parts of Herba Taraxacis, 23 parts of Herba Solani Nigris, 23 parts of Herba Artemisiae Scopariaes, 23 parts of Rhizoma Curcumae, 23 parts of Aspongopuss, 23 parts of Pseudobulbus Cremastrae Seu Pleioness, 13 parts of Spina Gleditsiaes, 23 parts of Rhizoma Paridis, 13 parts of Fructus Aurantiis, 18 parts of Herba Artemisiae Anomalaes, 23 parts of Concha Ostreae, 23 parts of Carapax Trionycis, 13 parts of the Radix Aucklandiae, 18 parts of Radix Codonopsis, 33 parts of Spica Prunellaes, 18 parts of Herba Salviae Chinensiss, 18 parts of Herba Verbenae, 8 parts of Rhizoma Alismatis, 8 parts of Polyporus, 13 parts of Semen Plantaginiss, 13 parts of Olibanums, 13 parts of Myrrhas, 13 parts of Rhizoma Corydalis, 13 parts of Radix Curcumaes, 13 parts of Cutis Bufonis, 8 parts of Herba Chelidoniis, 8 parts of Fructus Toosendans, 13 parts of Lignum Sappans, 13 parts of Radix Cynanchi Paniculatis, 6 parts of 6 parts of Radix Phytolaccaes and Semen Pharbitidiss.
Embodiment 5, a kind of medicine of Hepatoma therapy ascites, active ingredient comprises by weight: 16 parts of Radix Bupleuri, 16 parts of the Rhizoma Atractylodis Macrocephalaes, 21 parts of the Radix Paeoniae Albas, 16 parts of Pericarpium Citri Reticulataes, 11 parts of Flos Chrysanthemi, 11 parts of Radix Angelicae Sinensis, 16 parts of Radix Salviae Miltiorrhizaes, 21 parts of Fructus Akebiaes, 6 parts, Flos Carthami, 16 parts, Poria, 21 parts of Herba Scutellariae Barbataes, 21 parts of Rhizoma Sparganii, 31 parts of Rhizoma Polygoni Cuspidati, 11 parts of Cortex Moutans, 21 parts of Herba Taraxacis, 21 parts of Herba Solani Nigris, 21 parts of Herba Artemisiae Scopariaes, 21 parts of Rhizoma Curcumae, 21 parts of Aspongopuss, 21 parts of Pseudobulbus Cremastrae Seu Pleioness, 11 parts of Spina Gleditsiaes, 21 parts of Rhizoma Paridis, 11 parts of Fructus Aurantiis, 16 parts of Herba Artemisiae Anomalaes, 21 parts of Concha Ostreae, 21 parts of Carapax Trionycis, 11 parts of the Radix Aucklandiae, 16 parts of Radix Codonopsis, 31 parts of Spica Prunellaes, 16 parts of Herba Salviae Chinensiss, 16 parts of Herba Verbenae, 6 parts of Rhizoma Alismatis, 6 parts of Polyporus, 11 parts of Semen Plantaginiss, 11 parts of Olibanums, 11 parts of Myrrhas, 11 parts of Rhizoma Corydalis, 11 parts of Radix Curcumaes, 11 parts of Cutis Bufonis, 6 parts of Herba Chelidoniis, 6 parts of Fructus Toosendans, 11 parts of Lignum Sappans, 11 parts of Radix Cynanchi Paniculatis, 4 parts of 4 parts of Radix Phytolaccaes and Semen Pharbitidiss.
The medicine of above five embodiment is prepared according to following steps respectively:
A, take respectively each raw material according to weight portion;
B, Carapax Trionycis is faint yellow to surface with stir-baking in sand, takes out, quench in vinegar, and dry smashing to pieces, for subsequent use;
C, Radix Aucklandiae (roasted): get undried Radix Aucklandiae sheet, in iron wire plaque, use one deck toilet paper, one deck Radix Aucklandiae sheet, several layers of interval tilings, put in the other or drying chamber of stove fire, dry to simmer to contained volatile oil in the Radix Aucklandiae to ooze to paper, take out, for subsequent use;
D, Olibanum (processed): get the Olibanum of choosing clean, put in pot and fry and slightly see melting point to surface with slow fire, be slightly yellow, taking-up cools; Or fry while dissolving to surface, spray rice vinegar, continue stir-fry saturating to outer bright light, taking-up cools, for subsequent use;
E, Myrrha (processed): get the Myrrha of choosing clean put pot in slow fire fry slightly see melting point to surface, taking-up cools.Or fry slightly see fusing during to surface, spray rice vinegar, continue stir-fry saturating to outer bright light, taking-up cools, for subsequent use;
F, wine Rhizoma Corydalis: get clean Rhizoma Corydalis sheet or fragment, add yellow wine and mix thoroughly, vexed, put in pot and heat with slow fire, fried dry, taking-up cools, for subsequent use;
G, Rhizoma Atractylodis Macrocephalae (parched): processed with honey wheat bran is sprinkled in heat pot, adds Rhizoma Atractylodis Macrocephalae sheet in the time smoldering, fry to coke yellow, effusion burnt odor gas, take out, sieve removes processed with honey wheat bran, for subsequent use;
H, Radix Paeoniae Alba: get clean Radix Paeoniae Alba sheet, even with yellow wine sprinkling, slightly after profit, put an extremely micro-yellow of stir-fry in pot, for subsequent use;
J, remaining raw material and Carapax Trionycis (processed with vinegar) and Radix Aucklandiae (roasted), Olibanum (processed), Myrrha (processed), wine Rhizoma Corydalis, Rhizoma Atractylodis Macrocephalae (parched), Radix Paeoniae Alba are mixed, pulverize with pulverizer, crossing 120 mesh sieves becomes smalls, obtains the medicine of Hepatoma therapy ascites.
K, divide bag hermetic package by above smalls.
In step b, the weight ratio of Carapax Trionycis and vinegar is 5:1.
In steps d, the weight ratio of Olibanum and rice vinegar is 50:3.
The weight ratio of Myrrha and rice vinegar is 50:3.
The weight ratio of Rhizoma Corydalis and yellow wine is 5:1.
The weight ratio of the Rhizoma Atractylodis Macrocephalae and processed with honey wheat bran is 10:1.
The weight ratio of the Radix Paeoniae Alba and yellow wine is 10:1.
The using method of Hepatoma therapy ascites Chinese medicine comprises the following steps:
A, Chinese medicine smalls and the Mel of tempering are mixed to rubbing and ball, every pill 0.3g by 1:1.5.
30 of b, one time, every day three times is oral.
Test by above five embodiment gained medicines for hepatic ascites, is used efficacy assessment standard to be:
Effective: ascites and edema disappear completely, symptom alleviates or disappears, and tumor body dwindles; Stable: ascites does not disappear completely, and B ultrasonic is pointed out a small amount of ascites, and tumor body has no and dwindles, and also has no increase; Worsen: symptom increases the weight of, tumor body increases, ascites is not moved back, even occur hepatic coma, hemorrhage, shock phenomenon.
The 180 routine hepatic ascites patients that seek medical advice year October in July, 2010 to 2013, patient's disease meets " Internal Medicine-Oncology " the 3rd edition hepatic ascites diagnostic criteria.180 examples are all hepatocarcinoma through proved by pathology, and wherein 52 examples are diagnosed as hepatic ascites through B ultrasonic, and all the other 128 examples have ascites classical symptom.Man's 67 examples, female's 113 examples, age 40-80 year, the course of disease 1 month to 2 years.
5 test group are set altogether, and each test group random assortment patient treats.Test group 1 is used the Drug therapy of embodiment 1 gained, test group 2 is used the Drug therapy of embodiment 2 gained, test group 3 is used the Drug therapy of embodiment 3 gained, test group 4 is used the Drug therapy of embodiment 4 gained, test group 5 is used the Drug therapy of the embodiment of the present invention 5 gained, if 30 examples are matched group, matched group adopts the albuminous method treatment of the injection of doctor trained in Western medicine abdominal cavity, abdominal paracentesis and infusion, and total effective rate is 50%.
The result that obtains of test is as following table:
Find out from above data, the medicine of gained Hepatoma therapy ascites of the present invention, total effective rate reaches more than 60.0%, and without obvious toxic-side effects, in above embodiment, embodiment 4 is preferred plan, and effective percentage can reach 80%.
Unless stated otherwise, the degree relating to is mass percentage content.
Finally it should be noted that: the foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, although the present invention is had been described in detail with reference to previous embodiment, for a person skilled in the art, its technical scheme that still can record aforementioned each embodiment is modified, or part technical characterictic is wherein equal to replacement.Within the spirit and principles in the present invention all, any modification of doing, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (10)
1. a medicine for Hepatoma therapy ascites, is characterized in that: the active ingredient of described medicine comprises by weight: Radix Bupleuri 15-19 part, Rhizoma Atractylodis Macrocephalae 15-19 part, Radix Paeoniae Alba 20-24 part, Pericarpium Citri Reticulatae 15-19 part, Flos Chrysanthemi 10-14 part, Radix Angelicae Sinensis 10-14 part, Radix Salviae Miltiorrhizae 15-19 part, Fructus Akebiae 20-24 part, Flos Carthami 5-9 part, Poria 15-19 part, Herba Scutellariae Barbatae 20-24 part, Rhizoma Sparganii 20-24 part, Rhizoma Polygoni Cuspidati 30-34 part, Cortex Moutan 10-14 part, Herba Taraxaci 20-24 part, Herba Solani Nigri 20-24 part, Herba Artemisiae Scopariae 20-24 part, Rhizoma Curcumae 20-24 part, Aspongopus 20-24 part, Pseudobulbus Cremastrae Seu Pleiones 20-24 part, Spina Gleditsiae 10-14 part, Rhizoma Paridis 20-24 part, Fructus Aurantii 10-14 part, Herba Artemisiae Anomalae 15-19 part, Concha Ostreae 20-24 part, Carapax Trionycis 20-24 part, Radix Aucklandiae 10-14 part, Radix Codonopsis 15-19 part, Spica Prunellae 30-34 part, Herba Salviae Chinensis 15-19 part, Herba Verbenae 15-19 part, Rhizoma Alismatis 5-9 part, Polyporus 5-9 part, Semen Plantaginis 10-14 part, Olibanum 10-14 part, Myrrha 10-14 part, Rhizoma Corydalis 10-14 part, Radix Curcumae 10-14 part, Cutis Bufonis 10-14 part, Herba Chelidonii 5-9 part, Fructus Toosendan 5-9 part, Lignum Sappan 10-14 part, Radix Phytolaccae 3-7 part, Radix Cynanchi Paniculati 10-14 part and Semen Pharbitidis 3-7 part.
2. the medicine of Hepatoma therapy ascites as claimed in claim 1, is characterized in that: the active ingredient of described medicine comprises by weight: Radix Bupleuri 16-18 part, Rhizoma Atractylodis Macrocephalae 16-18 part, Radix Paeoniae Alba 21-23 part, Pericarpium Citri Reticulatae 16-18 part, Flos Chrysanthemi 11-13 part, Radix Angelicae Sinensis 11-13 part, Radix Salviae Miltiorrhizae 16-18 part, Fructus Akebiae 21-23 part, Flos Carthami 6-8 part, Poria 16-18 part, Herba Scutellariae Barbatae 21-23 part, Rhizoma Sparganii 21-23 part, Rhizoma Polygoni Cuspidati 31-33 part, Cortex Moutan 11-13 part, Herba Taraxaci 21-23 part, Herba Solani Nigri 21-23 part, Herba Artemisiae Scopariae 21-23 part, Rhizoma Curcumae 21-23 part, Aspongopus 21-23 part, Pseudobulbus Cremastrae Seu Pleiones 21-23 part, Spina Gleditsiae 11-13 part, Rhizoma Paridis 21-23 part, Fructus Aurantii 11-13 part, Herba Artemisiae Anomalae 16-18 part, Concha Ostreae 21-23 part, Carapax Trionycis 21-23 part, Radix Aucklandiae 11-13 part, Radix Codonopsis 16-18 part, Spica Prunellae 31-33 part, Herba Salviae Chinensis 16-18 part, Herba Verbenae 16-18 part, Rhizoma Alismatis 6-8 part, Polyporus 6-8 part, Semen Plantaginis 11-13 part, Olibanum 11-13 part, Myrrha 11-13 part, Rhizoma Corydalis 11-13 part, Radix Curcumae 11-13 part, Cutis Bufonis 11-13 part, Herba Chelidonii 6-8 part, Fructus Toosendan 6-8 part, Lignum Sappan 11-13 part, Radix Phytolaccae 4-6 part, Radix Cynanchi Paniculati 11-13 part and Semen Pharbitidis 4-6 part.
3. the medicine of Hepatoma therapy ascites as claimed in claim 1, it is characterized in that: the active ingredient of described medicine comprises by weight: 17 parts of Radix Bupleuri, 17 parts of the Rhizoma Atractylodis Macrocephalaes, 22 parts of the Radix Paeoniae Albas, 17 parts of Pericarpium Citri Reticulataes, 12 parts of Flos Chrysanthemi, 12 parts of Radix Angelicae Sinensis, 17 parts of Radix Salviae Miltiorrhizaes, 22 parts of Fructus Akebiaes, 7 parts, Flos Carthami, 17 parts, Poria, 22 parts of Herba Scutellariae Barbataes, 22 parts of Rhizoma Sparganii, 32 parts of Rhizoma Polygoni Cuspidati, 12 parts of Cortex Moutans, 22 parts of Herba Taraxacis, 22 parts of Herba Solani Nigris, 22 parts of Herba Artemisiae Scopariaes, 22 parts of Rhizoma Curcumae, 22 parts of Aspongopuss, 22 parts of Pseudobulbus Cremastrae Seu Pleioness, 12 parts of Spina Gleditsiaes, 22 parts of Rhizoma Paridis, 12 parts of Fructus Aurantiis, 17 parts of Herba Artemisiae Anomalaes, 22 parts of Concha Ostreae, 22 parts of Carapax Trionycis, 12 parts of the Radix Aucklandiae, 17 parts of Radix Codonopsis, 32 parts of Spica Prunellaes, 17 parts of Herba Salviae Chinensiss, 17 parts of Herba Verbenae, 7 parts of Rhizoma Alismatis, 7 parts of Polyporus, 12 parts of Semen Plantaginiss, 12 parts of Olibanums, 12 parts of Myrrhas, 12 parts of Rhizoma Corydalis, 12 parts of Radix Curcumaes, 12 parts of Cutis Bufonis, 7 parts of Herba Chelidoniis, 7 parts of Fructus Toosendans, 12 parts of Lignum Sappans, 5 parts of Radix Phytolaccaes, 5 parts of 12 parts of Radix Cynanchi Paniculatis and Semen Pharbitidiss.
4. as the preparation method of claim 1-3 Hepatoma therapy ascites medicine as described in one of them, it is characterized in that: described preparation method comprises the following steps:
A, take respectively each raw material according to weight portion;
B, Carapax Trionycis is faint yellow to surface with stir-baking in sand, takes out, quench in vinegar, and dry smashing to pieces, for subsequent use;
C, Radix Aucklandiae (roasted): get undried Radix Aucklandiae sheet, in iron wire plaque, use one deck toilet paper, one deck Radix Aucklandiae sheet, several layers of interval tilings, put in the other or drying chamber of stove fire, dry to simmer to contained volatile oil in the Radix Aucklandiae to ooze to paper, take out, for subsequent use;
D, Olibanum (processed): get the Olibanum of choosing clean, put in pot and fry and slightly see melting point to surface with slow fire, be slightly yellow, taking-up cools; Or fry while dissolving to surface, spray rice vinegar, continue stir-fry saturating to outer bright light, taking-up cools, for subsequent use;
E, Myrrha (processed): get the Myrrha of choosing clean and put in pot and fry and slightly see melting point to surface with slow fire, take out and cool or fry slightly sees fusing during to surface, spray rice vinegar, continue to fry to outer bright light saturating, taking-up cools, for subsequent use;
F, wine Rhizoma Corydalis: get clean Rhizoma Corydalis sheet or fragment, add yellow wine and mix thoroughly, vexed, put in pot and heat with slow fire, fried dry, taking-up cools, for subsequent use;
G, Rhizoma Atractylodis Macrocephalae (parched): processed with honey wheat bran is sprinkled in heat pot, adds Rhizoma Atractylodis Macrocephalae sheet in the time smoldering, fry to coke yellow, effusion burnt odor gas, take out, sieve removes processed with honey wheat bran, for subsequent use;
H, Radix Paeoniae Alba: get clean Radix Paeoniae Alba sheet, even with yellow wine sprinkling, slightly after profit, put an extremely micro-yellow of stir-fry in pot, for subsequent use;
J, remaining raw material and Carapax Trionycis (processed with vinegar) and Radix Aucklandiae (roasted), Olibanum (processed), Myrrha (processed), wine Rhizoma Corydalis, Rhizoma Atractylodis Macrocephalae (parched), Radix Paeoniae Alba are mixed, pulverize with pulverizer, crossing 120 mesh sieves becomes smalls, obtains the medicine of Hepatoma therapy ascites.
5. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in step b, the weight ratio of described Carapax Trionycis and vinegar is 5:1.
6. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in steps d, the weight ratio of described Olibanum and rice vinegar is 50:3.
7. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in step e, the weight ratio of described Myrrha and rice vinegar is 50:3.
8. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in step f, the weight ratio of described Rhizoma Corydalis and yellow wine is 5:1.
9. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in step g, the weight ratio of the described Rhizoma Atractylodis Macrocephalae and processed with honey wheat bran is 10:1.
10. the preparation method of Hepatoma therapy ascites medicine as claimed in claim 4, is characterized in that: in step h, the weight ratio of the described Radix Paeoniae Alba and yellow wine is 10:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410068364.3A CN103768542A (en) | 2014-02-27 | 2014-02-27 | Medicine for treating ascites due to liver cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410068364.3A CN103768542A (en) | 2014-02-27 | 2014-02-27 | Medicine for treating ascites due to liver cancer and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103768542A true CN103768542A (en) | 2014-05-07 |
Family
ID=50561602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410068364.3A Pending CN103768542A (en) | 2014-02-27 | 2014-02-27 | Medicine for treating ascites due to liver cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103768542A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173725A (en) * | 2014-08-28 | 2014-12-03 | 邓鑫 | Traditional Chinese medicine composition for treating ascites due to hepatic cancer |
| CN104689182A (en) * | 2015-03-23 | 2015-06-10 | 中国人民解放军济南军区第四五六医院 | Traditional Chinese medicine combination for treatment of liver cancer and preparation method thereof |
| CN107569600A (en) * | 2017-09-21 | 2018-01-12 | 江亮 | Chinese medicine composition of the anti-curing cancers of medicine-food two-purpose, wide spectrum and preparation method thereof |
| CN112274598A (en) * | 2020-12-08 | 2021-01-29 | 陈树亮 | Medicine for treating liver cancer and preparation method thereof |
| CN113413450A (en) * | 2016-08-31 | 2021-09-21 | 王清贤 | Traditional Chinese medicine composition for treating malignant pleural effusion and ascites as well as preparation method and application thereof |
-
2014
- 2014-02-27 CN CN201410068364.3A patent/CN103768542A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 陈世伟等主编: "《肿瘤中西医综合治疗》", 31 July 2001, 人民卫生出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173725A (en) * | 2014-08-28 | 2014-12-03 | 邓鑫 | Traditional Chinese medicine composition for treating ascites due to hepatic cancer |
| CN104689182A (en) * | 2015-03-23 | 2015-06-10 | 中国人民解放军济南军区第四五六医院 | Traditional Chinese medicine combination for treatment of liver cancer and preparation method thereof |
| CN104689182B (en) * | 2015-03-23 | 2016-01-20 | 中国人民解放军济南军区第四五六医院 | Chinese medicine composition of a kind of Hepatoma therapy and preparation method thereof |
| CN113413450A (en) * | 2016-08-31 | 2021-09-21 | 王清贤 | Traditional Chinese medicine composition for treating malignant pleural effusion and ascites as well as preparation method and application thereof |
| CN107569600A (en) * | 2017-09-21 | 2018-01-12 | 江亮 | Chinese medicine composition of the anti-curing cancers of medicine-food two-purpose, wide spectrum and preparation method thereof |
| CN112274598A (en) * | 2020-12-08 | 2021-01-29 | 陈树亮 | Medicine for treating liver cancer and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518807C (en) | A Medicine for treatment of ascites due to cirrhosis | |
| CN103768542A (en) | Medicine for treating ascites due to liver cancer and preparation method thereof | |
| CN102988656A (en) | Traditional Chinese medicine composition for treating acute pancreatitis | |
| CN102512632B (en) | Chinese herbal composition for treating abnormal menstruation | |
| CN105250813A (en) | Chinese herb composition for treating jaundice | |
| CN104524159A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands | |
| CN104435686A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating skin itch and eczema papulosum | |
| CN103816497A (en) | Traditional Chinese medicinal composition for treating syndrome of liver qi stagnation | |
| CN102805844A (en) | Medicine for treating liver cancer | |
| CN104523873A (en) | Pharmaceutical composition for treating gout | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN104189778A (en) | Traditional Chinese medicine preparation for hyperplasia of mammary glands and preparation method of traditional Chinese medicine preparation | |
| CN106110186A (en) | A kind of Chinese medicine composition suppressing tumor-blood-vessel growth, anti-tumor to shift | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN105878829A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN103479949A (en) | Medicine for preventing and treating constipation | |
| CN104825892B (en) | A kind of Chinese medicine preparation for treating ovulation bleeding and preparation method thereof | |
| CN104645247B (en) | A kind of Chinese medicine preparation for treating hepatolenticular degeneration and preparation method thereof | |
| CN107753800A (en) | A kind of Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN107320615B (en) | Traditional Chinese medicine preparation for treating laryngitis and preparation method thereof | |
| CN101081293A (en) | Capsules preparations for preventing and treating hepatic disease by dispersing blood-stasis of portal vein | |
| CN104922595A (en) | Traditional Chinese medicinal preparation for herpes zoster and preparation method thereof | |
| CN103479950A (en) | Preparation method of medicine for preventing and treating constipation | |
| CN103479948A (en) | Medicine for preventing and treating constipation | |
| CN104689093A (en) | Medicine for treating proliferation of mammary gland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140507 |